Aviragen Therapeutics (AVIR) Misses Q4 EPS by 13c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.57), $0.13 worse than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Apple alleges defendant in trade secret case against OpenAI accessed power converter circuit schematic while at OpenAI - legal filing
• Kohl's names Ryan Waymire as chief merchandising officer
• IHT converts $3M debt to equity to meet NYSE American listing rules